Literature DB >> 26942095

First oncolytic virus approved for melanoma immunotherapy.

Jonathan Pol1, Guido Kroemer2, Lorenzo Galluzzi3.   

Abstract

On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

Entities:  

Keywords:  Granulocyte macrophage colony-stimulating factor; Imlygic®; OPTiM; OncoVEXGM-CSF; T-vec; talimogene laherparepvec

Year:  2015        PMID： 26942095      PMCID： PMC4760283          DOI： 10.1080/2162402X.2015.1115641

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  38 in total

1.  Oncolytic viruses get a boost with first FDA-approval recommendation.

Authors:  Elie Dolgin
Journal:  Nat Rev Drug Discov       Date:  2015-06       Impact factor: 84.694

Review 2.  Trial Watch: Radioimmunotherapy for oncological indications.

Authors:  Norma Bloy; Jonathan Pol; Gwenola Manic; Ilio Vitale; Alexander Eggermont; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

Review 3.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

4.  The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha.

Authors:  K A Cassady; M Gross; B Roizman
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

Review 5.  Trial Watch: Immunostimulatory cytokines.

Authors:  Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-05-07       Impact factor: 8.110

6.  Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization.

Authors:  Tuuli Ranki; Timo Joensuu; Elke Jäger; Julia Karbach; Claudia Wahle; Kalevi Kairemo; Tuomo Alanko; Kaarina Partanen; Riku Turkki; Nina Linder; Johan Lundin; Ari Ristimäki; Matti Kankainen; Akseli Hemminki; Charlotta Backman; Kasper Dienel; Mikael von Euler; Elina Haavisto; Tiina Hakonen; Juuso Juhila; Magnus Jaderberg; Petri Priha; Lotta Vassilev; Antti Vuolanto; Sari Pesonen
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

7.  Cancer immunotherapy turns viral.

Authors:  Lorenzo Galluzzi; Enrico Lugli
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

8.  Rewiring cancer cell death to enhance oncolytic viro-immunotherapy.

Authors:  Samuel T Workenhe; Karen L Mossman
Journal:  Oncoimmunology       Date:  2013-12-09       Impact factor: 8.110

Review 9.  Trial Watch:: Oncolytic viruses for cancer therapy.

Authors:  Jonathan Pol; Norma Bloy; Florine Obrist; Alexander Eggermont; Jérôme Galon; Isabelle Cremer; Philippe Erbs; Jean-Marc Limacher; Xavier Preville; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-06-01       Impact factor: 8.110

Review 10.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694
View more
  97 in total

Review 1.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Authors:  Melody Smith; Elena García-Martínez; Michael R Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

Review 2.  Next-generation stem cells - ushering in a new era of cell-based therapies.

Authors:  Erin A Kimbrel; Robert Lanza
Journal:  Nat Rev Drug Discov       Date:  2020-04-06       Impact factor: 84.694

3.  Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC.

Authors:  Yonghui Zhang; Hailin Zhang; Mei Wei; Tao Mou; Tao Shi; Yanyu Ma; Xinyu Cai; Yunzheng Li; Jie Dong; Jiwu Wei
Journal:  Mol Ther       Date:  2019-08-05       Impact factor: 11.454

Review 4.  Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world.

Authors:  Kenzaburo Tani
Journal:  Int J Hematol       Date:  2016-06-11       Impact factor: 2.490

Review 5.  New insights on the role of autophagy in the pathogenesis and treatment of melanoma.

Authors:  Marveh Rahmati; Shiva Ebrahim; Saadeh Hashemi; Masoumeh Motamedi; Mohammad Amin Moosavi
Journal:  Mol Biol Rep       Date:  2020-10-09       Impact factor: 2.316

Review 6.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

Review 7.  Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Authors:  Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

Review 8.  Nanoparticle-based approaches to target the lymphatic system for antitumor treatment.

Authors:  Xingzhou Peng; Junjie Wang; Feifan Zhou; Qian Liu; Zhihong Zhang
Journal:  Cell Mol Life Sci       Date:  2021-05-08       Impact factor: 9.261

9.  The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model.

Authors:  Rui Tanaka; Fumi Goshima; Shinichi Esaki; Yoshitaka Sato; Takayuki Murata; Yukihiro Nishiyama; Daisuke Watanabe; Hiroshi Kimura
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

Review 10.  Retargeting of herpes simplex virus (HSV) vectors.

Authors:  William F Goins; Bonnie Hall; Justus B Cohen; Joseph C Glorioso
Journal:  Curr Opin Virol       Date:  2016-09-08       Impact factor: 7.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.